| 52 Week Rng | - |
| Market Cap | - |
| Avg Volume | - |
| 1M Volatility | - |
| Short Ratio | - |
| P/E Ratio (TTM) | - |
| P/E Ratio (Fwd) | - |
| P/B Ratio | - |
| Div & Yield | - |
leoleppaaho • Aalto Investment Management Game (Fall 2020) • Dec 2020
Passive buy-and-hold strategy based on momentum and diversification | Long position: 10 companies with the highest YTD-earnings from 3 different sectors + 1 ETF with the highest YTD-earnings in its sector | equally weighted between the four sectors | adjusting weights 12/02/20
leoleppaaho • Stockfuse Continuum (US) • Dec 2020
Passive buy-and-hold strategy based on momentum and diversification | Long position: 10 companies with the highest YTD-earnings from 3 different sectors + 1 ETF with the highest YTD-earnings in its sector | equally weighted between the four sectors | adjusting weights 12/02/20
AIJOFund • Aalto Investment Management Game (Fall 2020) • Nov 2020
Momentum strategy | Equal weighting | Long position: 30 stocks with highest cumulative returns during the last 12 months | Rank 10
*Includes only companies available in the game
lord_mack21 • Long Term Value Investment Challenge • Jul 2020
Automatic trade executed by Stockfuse to ensure margin compliance.
RehanShah • Stockfuse Continuum (US) • Jul 2020
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™ and NasoShield™). Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate. Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients with Early COVID-19. Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell™ Immunotherapeutic for the Treatment of Chronic Hepatitis B. Altimmune’s Largest Investor Sees Potential Coronavirus Vaccine, Buys More Stock.